Int J Cardiol:免疫检查点抑制剂相关性心肌炎的诊断

2019-07-12 xing.T MedSci原创

由此可见,免疫检查点抑制剂相关性心肌炎的特征是心肌肌钙蛋白水平升高和非特异性心电图改变。早期冠状动脉造影可将其与心肌缺血或心肌梗塞区分开来。

心肌炎是一种罕见但严重的与免疫检查点抑制剂相关的不良事件,其诊断依赖于高度怀疑和适当的检查。近日,心血管领域权威杂志International Journal of Cardiology上发表了一篇研究文章,研究人员的目标是系统地评估与免疫检查点抑制剂相关的心肌炎的诊断方法。 

该系统评价根据PRISMA指南(PROSPERO注册:CRD42018097247)进行。研究人员在Medline和Embase上检索了在期刊文章中发表的病例报告、病例系列和观察性研究,或者描述免疫检查点抑制剂治疗后发生心肌炎的患者会议摘要。

在对2326次引用文献进行审查后,研究人员纳入了88例病例(病例报告和病例系列中的53例,以及观察性研究中的35例)。98%的病例报告和94%的观察性研究参与者血清肌钙蛋白升高。几乎三分之一的病例报告中都有ST改变,包括ST段抬高。超声心动图显示32%的病例报告和51%的观察研究中病例左心室射血分数正常;然而,收缩功能正常并不能预测更大的生存率。预后较差的患者比没有预后较差的患者更容易出现严重的传导缺陷或室性心律失常。当诊断检查包括冠状动脉造影时,所有病例(n=31)都排除了急性心肌缺血。

由此可见,免疫检查点抑制剂相关性心肌炎的特征是心肌肌钙蛋白水平升高和非特异性心电图改变。早期冠状动脉造影可将其与心肌缺血或心肌梗塞区分开来。 

原始出处:

RicheekPradhan,et al.Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review.International Journal of Cardiology.2019.https://doi.org/10.1016/j.ijcard.2019.07.025

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782048, encodeId=55de1e8204856, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 10 11:03:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837707, encodeId=1d4a183e7079b, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Nov 22 12:03:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852051, encodeId=0e6018520512a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 19 23:03:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340516, encodeId=43b81340516c9, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Jul 13 23:03:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782048, encodeId=55de1e8204856, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 10 11:03:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837707, encodeId=1d4a183e7079b, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Nov 22 12:03:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852051, encodeId=0e6018520512a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 19 23:03:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340516, encodeId=43b81340516c9, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Jul 13 23:03:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782048, encodeId=55de1e8204856, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 10 11:03:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837707, encodeId=1d4a183e7079b, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Nov 22 12:03:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852051, encodeId=0e6018520512a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 19 23:03:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340516, encodeId=43b81340516c9, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Jul 13 23:03:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]
    2020-04-19 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=1782048, encodeId=55de1e8204856, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Oct 10 11:03:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837707, encodeId=1d4a183e7079b, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Nov 22 12:03:00 CST 2019, time=2019-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852051, encodeId=0e6018520512a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 19 23:03:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340516, encodeId=43b81340516c9, content=<a href='/topic/show?id=dd1a29055c8' target=_blank style='color:#2F92EE;'>#免疫检查点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29055, encryptionId=dd1a29055c8, topicName=免疫检查点)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Sat Jul 13 23:03:00 CST 2019, time=2019-07-13, status=1, ipAttribution=)]

相关资讯

Nat Med:TIDE评分,创新性的免疫检查点抑制治疗预后评估方案

一直以来,如何评估免疫检查点抑制治疗的预后效果都是广大肿瘤医生所面临的问题,一方面“神药”会给部分患者带来起死回生的效果,另一方面使用不当也很有可能适得其反,而单一的生物标志物也越来越不能满足实际应用的需要,综合多种数据类型形成合适的评分规则也越来越受到人们的关注。

JAMA Oncol:免疫检查点抑制剂相关致命性并发症 你造吗?

免疫检查点抑制剂(ICIs)目前是癌症治疗的革命性突破和支柱。虽然罕见,但爆发性和致命性毒性反应会使这些革命性疗法变得复杂化,描述这些事件需要整合全球数据。2018年12月,发表在《JAMA Oncol》的一项系统评价和Meta分析调查了,与免疫检查点抑制剂相关的致命毒性反应。

PNAS:癌中之王的“阿喀琉斯之踵”——VISTA

虽然目前的免疫检查点抑制剂疗法对胰腺癌基本上无效,但美国科学家现在已经确定了一种免疫检查点分子,它可以代表这种肿瘤类型的有希望的免疫治疗靶点。德克萨斯大学MD安德森癌症中心领导的研究小组发现,与黑色素瘤相比,T细胞活化的V结构域免疫球蛋白抑制剂(VISTA)优先在胰腺癌中高水平表达。研究人员的研究还提供了与黑色素瘤相比较的原发性和转移性胰腺癌免疫浸润的详细分析,这可能进一步有助于指导针对胰腺癌治疗

Cell:一个新的“免疫检查点”,有望与癌症疫苗联合抗癌

Cell最新一篇文章揭示了一种全新的癌症免疫疗法。

Lancet Oncol:警示!免疫检查点抑制剂会导致严重心血管毒性

癌症免疫疗法改变了癌症的治疗,但免疫治疗相关的不良事件也较常见。2018年12月,发表在《Lancet Oncol》的一项观察性、回顾性、药物警戒研究调查了,免疫检查点抑制剂(ICIs)相关的心血管毒性。

NJEM:免疫检查点抑制剂联合阿西替尼,治疗晚期肾癌显疗效

过去12年中,转移性肾细胞癌的治疗已经彻底改变了两次。临床数据显示血管内皮生长因子(VEGF)抑制可以诱导肿瘤缩小并增加无进展生存期,而免疫检查点抑制剂可以诱导持久反应并增加这种癌症患者的总体生存率。